Scoop has an Ethical Paywall
Roche Position Statement Regarding Herceptin
14 February 2006
Roche Position Statement Regarding Herceptin
Roche Products (NZ) Limited is working proactively and constructively with both Medsafe and Pharmac to ensure the fastest possible access to Herceptin for HER2 positive women with early breast cancer in New Zealand. The regulatory submission to permit the extension of licensed use of Herceptin for early breast cancer was submitted to Medsafe in November.
The clinical evidence dossier required as part of the reimbursement process for Herceptin in early stage disease was submitted to Pharmac in December.
We are currently completing an additional dossier for Pharmac to demonstrate the cost-effectiveness of Herceptin in this setting and aim to have this completed by early March. Roche cannot speculate on the expected timelines these processes may take, but we commit to responding as promptly as possible to any additional requests for information that either agency may require as part of their assessment process.
ENDS
International Writers' Workshop NZ Inc: Ōtepoti Poets Top The Kathleen Grattan Prize For A Sequence Of Poems
NZ Amateur Sport Association: 22 Amendments Proposed For 2022 Act Lodged On 22 November
Auckland University of Technology: Reading Helps Children Face A Difficult Future
PATHA: Puberty Blocker Evidence Brief Affirms Aotearoa’s Approach
Tataki Auckland Unlimited: Into Ocean & Ice - Unveiling Antarctica's Past And Present
Health Coalition Aotearoa: Urgent Action Needed To Address Aotearoa’s Shameful Household Food Insecurity